Celltrion Pharm said on the 6th that it posted 132.1 billion won in revenue and 12.9 billion won in operating profit in the first quarter. Revenue rose 17% from a year earlier, and operating profit increased 20%.
The chemical business generated 54.4 billion won in revenue, up 6% from the same period a year earlier. Sales of Godex, a liver health medicine, were 17.6 billion won, and sales of Dilatrend, a hypertension treatment, were 14.9 billion won. Sales also increased for Amlodjet, a combination drug that treats hypertension and hyperlipidemia.
The bio business recorded 34.4 billion won in revenue, up 60% from a year earlier. Results were strong for Remsima (12.7 billion won), the anticancer drugs Vegzelma (3.9 billion won) and Truxima (3.7 billion won), and the bone disease treatment Stoboclo (2.7 billion won). In addition, contract manufacturing revenue was 36.6 billion won, up 22% from a year earlier.
A Celltrion Pharm official said, "Chemical sales were stable and the bio institutional sector grew," adding, "We will continue to expand our product portfolio."